Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Fig. 2

Human epidermal growth factor receptor 2 (HER2) membrane (Mem) analyses. a HER2 membrane scores versus outcome (pathologic complete response (pCR)) in all four treatment groups. b HER2 membrane staining intensity versus outcome in all four treatment groups (patients with missing pCR were excluded). c HER2 membrane score by outcome

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us